Jazz Pharma director sells 2,000 shares at $241

Jazz Pharmaceuticals plc director Heather Ann McSharry reported an open-market sale of 2,000 Ordinary Shares of the company on May 22, 2026 at a price of $241.00 per share.

Accepted by SEC EDGAR 05/27/2026 - 06:07 PM EDT

Filing Impact

(Neutral)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Jazz Pharmaceuticals plc director Heather Ann McSharry reported an open-market sale of 2,000 Ordinary Shares of the company on May 22, 2026 at a price of $241.00 per share. After this transaction, she directly holds 18,449 Ordinary Shares of Jazz Pharmaceuticals.

Insider Trade Summary

Net Seller: 2,000 shares

Net Sell 1 txn

Insider McSharry Heather Ann

Role Director

Sold 2,000 shs ($482K)

Share of Position Sold 9.8%

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	2,000	$241.00	$482K

Holdings After Transaction: Ordinary Shares — 18,449 shares (Direct)

Holdings Before and After: Ordinary Shares, 20,449 to 18,449 shares (Direct)

Other Insiders: 2 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Key Figures

Shares sold: 2,000 shares Sale price: $241.00 per share Shares held after transaction: 18,449 shares

3 metrics

Shares sold 2,000 shares Open-market sale on May 22, 2026

Sale price $241.00 per share Price for Ordinary Shares sold

Shares held after transaction 18,449 shares Direct ownership following sale

Key Terms

Ordinary Shares, open-market sale, Form 4, transaction code "S"

4 terms

Ordinary Shares financial

"security_title: "Ordinary Shares""

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"insider trading report disclosed on a Form 4"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

transaction code "S" regulatory

"transaction_code_description: "Sale in open market or private transaction""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Jazz Pharmaceuticals (JAZZ) report for Heather Ann McSharry?

Jazz Pharmaceuticals reported that director Heather Ann McSharry sold 2,000 Ordinary Shares in an open-market transaction. The sale occurred at a price of $241.00 per share and was disclosed on a Form 4 insider trading report.

How many Jazz Pharmaceuticals (JAZZ) shares did Heather Ann McSharry sell and at what price?

Heather Ann McSharry sold 2,000 Ordinary Shares of Jazz Pharmaceuticals at $241.00 per share. This was an open-market sale transaction reported as a code “S” on the Form 4 insider filing for Ordinary Shares.

What are Heather Ann McSharry’s holdings in Jazz Pharmaceuticals (JAZZ) after this Form 4 sale?

Following the reported sale, Heather Ann McSharry directly holds 18,449 Ordinary Shares of Jazz Pharmaceuticals. This post-transaction figure reflects her remaining direct ownership after selling 2,000 shares at $241.00 per share in the open market.

Was the Jazz Pharmaceuticals (JAZZ) insider trade a buy or a sell transaction?

The insider trade reported for Jazz Pharmaceuticals was a sell transaction. Director Heather Ann McSharry executed an open-market sale (transaction code S), disposing of 2,000 Ordinary Shares at a price of $241.00 per share.

What does transaction code “S” mean in the Jazz Pharmaceuticals (JAZZ) Form 4 filing?

In this Form 4, transaction code “S” indicates a sale in an open market or private transaction. For Jazz Pharmaceuticals, it shows that director Heather Ann McSharry sold 2,000 Ordinary Shares at $241.00 per share rather than acquiring additional shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McSharry Heather Ann

(Last)

(First)

(Middle)

5TH FL, WATERLOO EXCHANGE

WATERLOO RD

(Street)

DUBLIN 4

(City)

(State)

(Zip)

IRELAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
Jazz Pharmaceuticals plc [ JAZZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	05/22/2026		S		2,000	D	$241	18,449	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

	By: /s/Paz Dizon, as attorney in fact For: Heather Ann McSharry	05/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR